# BCAT2

## Overview
The BCAT2 gene encodes the mitochondrial enzyme branched-chain amino acid transaminase 2, which plays a pivotal role in the catabolism of branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine. This enzyme is classified as a transaminase and is essential for the reversible transamination process that converts BCAAs into their corresponding branched-chain keto acids (BCKAs), facilitating energy production and nitrogen balance within cells (Mann2021Branchedchain; Cao2024Multiomics). BCAT2 is predominantly active in the mitochondria of skeletal muscle cells, where it significantly contributes to muscle protein synthesis and energy metabolism (Mann2021Branchedchain). The enzyme's activity is modulated by various post-translational modifications and protein interactions, which influence its stability and function (Mann2021Branchedchain). Clinically, alterations in BCAT2 expression and function are associated with metabolic disorders and cancer, highlighting its importance in both normal physiology and disease states (Cao2024Multiomics; Knerr2019Expanding).

## Structure
The BCAT2 protein is a mitochondrial enzyme involved in the catabolism of branched-chain amino acids. Its primary structure is encoded by the BCAT2 gene and includes a sequence of amino acids that form the basis for its functional conformation (Nong2022The). The secondary structure of BCAT2 consists of alpha-helices and beta-sheets, which contribute to its stability and function (Conway2021Emerging). 

In terms of tertiary structure, BCAT2 forms a specific three-dimensional shape that includes a pyridoxal phosphate (PLP) cofactor binding site, essential for its enzymatic activity (Conway2021Emerging). The protein functions as a homodimer, representing its quaternary structure, which is crucial for its biological activity (Knerr2019Expanding). 

BCAT2 is characterized by a conserved active site, which involves a Schiff base linkage between the PLP cofactor and a lysine residue, facilitating its catalytic function (Conway2021Emerging). The substrate binding pocket is lined with hydrophobic side chains, aiding in substrate anchoring (Conway2021Emerging). Post-translational modifications, such as phosphorylation, may influence the activity and stability of BCAT2, although specific modifications are not detailed in the provided context (Nong2022The).

## Function
The BCAT2 gene encodes the mitochondrial isoform of branched-chain aminotransferase, an enzyme crucial for the metabolism of branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine. This enzyme facilitates the reversible transamination of BCAAs into their respective branched-chain keto acids (BCKAs) by transferring an amino group to α-ketoglutarate, producing glutamate. This process is essential for energy production and nitrogen balance in cells (Mann2021Branchedchain; Cao2024Multiomics).

BCAT2 is predominantly active in the mitochondria of skeletal muscle cells, where it accounts for a significant portion of whole-body BCAA catabolism. This activity is vital for muscle protein synthesis and energy metabolism, impacting muscle function and overall metabolic health (Mann2021Branchedchain). The enzyme's function is regulated by various factors, including post-translational modifications and interactions with other proteins, which influence its stability and activity (Mann2021Branchedchain).

In healthy human cells, BCAT2 plays a role in maintaining BCAA homeostasis, which is crucial for muscle growth, differentiation, and repair. It is also involved in the detoxification of ammonia, particularly in conditions affecting the liver and urea cycle (Mann2021Branchedchain; Dhanani2019Depletion).

## Clinical Significance
Mutations and alterations in the BCAT2 gene have significant clinical implications, particularly in metabolic and neurological disorders. BCAT2 deficiency, an ultra-rare condition caused by mutations in the BCAT2 gene, leads to elevated levels of branched-chain amino acids (BCAAs) in the plasma. This condition is characterized by a distinct biochemical profile with high BCAAs and low branched-chain keto acids (BCKAs), differentiating it from maple syrup urine disease (MSUD) (Knerr2019Expanding). Clinically, BCAT2 deficiency presents a wide range of phenotypes, including developmental delay, autism spectrum disorder, and intellectual disability, although the direct relationship between these symptoms and BCAT2 deficiency remains unclear (Knerr2019Expanding).

In cancer, BCAT2 expression is altered across various types, serving as a potential biomarker for tumor progression. It is upregulated in several cancers, such as breast, liver, and prostate, and downregulated in thyroid cancer (Cao2024Multiomics). In pancreatic ductal adenocarcinoma (PDAC), BCAT2 acetylation at lysine 44 promotes its degradation, suppressing BCAA catabolism and tumor growth, suggesting a potential therapeutic target (Lei2020Acetylation). BCAT2's role in metabolic reprogramming and immune modulation further underscores its clinical significance in cancer (Cao2024Multiomics).

## Interactions
BCAT2, a mitochondrial enzyme involved in branched-chain amino acid (BCAA) catabolism, participates in several protein interactions that influence its function and stability. BCAT2 interacts with the branched-chain α-keto acid dehydrogenase (BCKD) complex, promoting flux through the BCAA catabolic pathway, which is crucial for muscle cell differentiation (Dhanani2019Depletion). This interaction is significant for the production of substrates and reduced equivalents necessary for myotube formation (Dhanani2019Depletion).

BCAT2 is also regulated through acetylation, which affects its stability. The CREB-binding protein (CBP) acts as an acetyltransferase, acetylating BCAT2 at lysine 44, promoting its degradation via the ubiquitin-proteasome pathway. This interaction is confirmed through a His-BCAT2 pull-down assay (Lei2020Acetylation). Conversely, SIRT4 functions as a deacetylase, stabilizing BCAT2 by decreasing its acetylation and ubiquitylation, also verified by a His-BCAT2 pull-down assay (Lei2020Acetylation).

In cancer, BCAT2 interacts with metabolic proteins such as GCLC and BCK, indicating its involvement in key metabolic pathways and supporting its role in cancer metabolism and progression (Cao2024Multiomics). These interactions highlight BCAT2's multifaceted role in cellular metabolism and its potential impact on disease states.


## References


[1. (Conway2021Emerging) Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. Antioxidants &amp; Redox Signaling, 34(13):1048–1067, May 2021. URL: http://dx.doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 9 citations.](https://doi.org/10.1089/ars.2020.8118)

[2. (Mann2021Branchedchain) Gagandeep Mann, Stephen Mora, Glory Madu, and Olasunkanmi A. J. Adegoke. Branched-chain amino acids: catabolism in skeletal muscle and implications for muscle and whole-body metabolism. Frontiers in Physiology, July 2021. URL: http://dx.doi.org/10.3389/fphys.2021.702826, doi:10.3389/fphys.2021.702826. This article has 101 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2021.702826)

[3. (Nong2022The) Xiazhen Nong, Caiyun Zhang, Junmin Wang, Peilun Ding, Guang Ji, and Tao Wu. The mechanism of branched-chain amino acid transferases in different diseases: research progress and future prospects. Frontiers in Oncology, September 2022. URL: http://dx.doi.org/10.3389/fonc.2022.988290, doi:10.3389/fonc.2022.988290. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.988290)

[4. (Cao2024Multiomics) Qixuan Cao, Jie Fan, Jian Zou, and Wei Wang. Multi-omics analysis identifies bcat2 as a potential pan-cancer biomarker for tumor progression and immune microenvironment modulation. Scientific Reports, October 2024. URL: http://dx.doi.org/10.1038/s41598-024-74441-1, doi:10.1038/s41598-024-74441-1. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-74441-1)

[5. (Knerr2019Expanding) Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42(5):809–817, August 2019. URL: http://dx.doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jimd.12135)

[6. (Dhanani2019Depletion) Zameer N. Dhanani, Gagandeep Mann, and Olasunkanmi A. J. Adegoke. Depletion of branched‐chain aminotransferase 2 (bcat2) enzyme impairs myoblast survival and myotube formation. Physiological Reports, December 2019. URL: http://dx.doi.org/10.14814/phy2.14299, doi:10.14814/phy2.14299. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.14814/phy2.14299)

[7. (Lei2020Acetylation) Ming-Zhu Lei, Xu-Xu Li, Ye Zhang, Jin-Tao Li, Fan Zhang, Yi-Ping Wang, Miao Yin, Jia Qu, and Qun-Ying Lei. Acetylation promotes bcat2 degradation to suppress bcaa catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy, May 2020. URL: http://dx.doi.org/10.1038/s41392-020-0168-0, doi:10.1038/s41392-020-0168-0. This article has 64 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41392-020-0168-0)